Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 908 participants.
Also called NCT03684642
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 908 participants
- Registry
-
NCT03684642 -
2017-002956-10
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Hungary, Poland, Ukraine
- Registry status
- Terminated
Technical summary
Registry record NCT03684642. Randomized; no masking; primary purpose treatment. Start 2018-09-26 (actual); primary completion 2020-10-13 (actual). Results posted on 2021-11-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
- Acronym
- AMPLITUDE-D
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Efpeglenatide
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Background therapy Metformin
- Lead sponsor
- Sanofi
- Collaborator
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct03684642- Content hash
3292ea00ed3e1ecacc6aef3722344f88142d9b424319c2de91389b2e42a66d2c